The current size of the plasma fractionation market was estimated using four primary activities in this study. To gather information on the market, its peer markets, and its parent market, extensive secondary research was conducted. The next stage was to conduct primary research to confirm these findings, assumptions, and sizing with industry experts across the value chain. To estimate the total market size, top-down and bottom-up methodologies were used. The market size of segments and subsegments was then estimated using market breakdown and data triangulation processes.
Expected Revenue Growth in Plasma Fractionation Market Size:
[Report of 278 pages] The global plasma fractionation market is expected to grow at a CAGR of 6.7 percent over the forecast period, from USD 28.6 billion in 2020 to USD 39.5 billion in 2025. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), expanding elderly population, and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD). However, during the forecast period, the high cost of plasma products, restricted reimbursements, and the advent of recombinant alternatives are projected to hinder the market’s growth.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
Immunoglobins accounted for the highest share of the plasma fractionation market in 2019.
The plasma fractionation market is divided into immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products based on the kind of product. Immunoglobulins held the highest proportion of the worldwide plasma fractionation market in 2019, according to Industry Analysis. The growing usage of SCIg because to its simplicity of administration and reduced administration time is mostly linked to the rising prevalence of neurological and immunological illnesses, as well as increasing off-label indications for IVIg.
During the projected period, the pulmonology segment is expected to develop at the fastest CAGR.
The plasma fractionation market is divided into neurology, immunology, haematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications, depending on the application. During the projected period, the pulmonology segment is expected to have the greatest CAGR in 2019. The increased frequency of alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease are driving this market segment’s growth (copd).
In 2019, the largest regional market for North America.
The market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa on a geographical basis. North America held the highest proportion of the
market in 2019, followed by Europe and Asia Pacific. The growing usage of immunoglobulins in many therapeutic fields, the growing elderly population, and the rising prevalence of respiratory disorders and AATD are all factors contributing to North America’s big proportion of the global market.
Request Sample Report on Market:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=93798284
Key Players In Market:
Key players in the global market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), and BPL (UK), Sanquin (Netherlands),
